CA Medical - Page 5
Home CA Medical
California Medical News - including research, biotech, medical services and related
Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes
SAN MARINO, Calif. -- Epeius Biotechnologies (www.epeiusbiotech.com) announced today that the results of a Phase I Feasibility Study of sequential targeted gene delivery-using Rexin-G...
Rexin-G Monotherapy Reveals Significant Biological Activity without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
SAN MARINO, Calif. -- Epeius Biotechnologies announced today the promising results of an on-going United States-based Phase I/II study of Rexin-G for metastatic breast...
M2SYS Fingerprint Software Selected by Innovative Marijuana Caregiver Logistics
SANTA BARBARA, Calif. -- M2SYS Technology, an award-winning fingerprint biometrics research and development firm, announced today that it has finalized an agreement with IMCL...
ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity without Toxicity in Metastatic Pancreatic Cancer
SAN MARINO, Calif. -- Epeius Biotechnologies announced today the results of an on-going Phase I/II study of Rexin-G for metastatic pancreatic cancer (Chawla et...
Northern California Physician Incorporates His Personal Experience Into an Individualized Treatment Approach for Optimizing Fertility
SACRAMENTO, Calif. -- 7.3 million women experience infertility each year in the U.S. alone. In fact, 1 in 5 women have difficulty conceiving as more women than ever are having their first or subsequent child after the age of 35, a contributing factor of infertility. Enter Dr. Robert Greene's forthcoming book, "PERFECT HORMONE BALANCE FOR FERTILITY: The Ultimate Guide to Getting Pregnant" (ISBN: 978-0-307-33740-5).
Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today that Interim Analysis of an on-going Phase I/II study of Rexin-G for pancreatic cancer confirmed Rexin-G's anti-tumor activity with no major toxicity in patients with metastatic chemotherapy-resistant pancreatic cancer. The clinical trial design includes 5 escalating doses of intravenous Rexin-G ranging from 1 x 10e11 cfu twice a week to 4 x 10e11 cfu three times a week for 4 weeks. Treatment cycles are repeated if the patient exhibits Grade 1 or less toxicity.
Cypress Systems, Inc. Launches Cancer Prevention Health Campaign
FRESNO, Calif. -- Chairman and CEO, Paul Willis stated, "Just like his previous career at a large agribusiness company, Dr. Mark E. Whitacre has risen fast at Cypress Systems, Inc, last month being named the company's chief operating officer and president of operations." Now Cypress and Whitacre are focusing their energy on an aggressive cancer prevention campaign in order to get Americans-and people around the world-to consume a special type of selenium. Mark Whitacre, Ph.D. Promoted to COO at Cypress Systems, Inc. and a Warner Bros. Movie to be Filmed About Him
FRESNO, Calif. -- Cypress Systems, Inc, a Fresno CA based biotechnology company, announced that it has promoted Mark E. Whitacre, Ph.D. to become the company's Chief Operating Officer (COO) and President of Operations. Dr. Whitacre joined the executive management team in December 2006 as President of Technology and Business Development for the new east coast office. 
Epeius Bio Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today the issue of U.S. Patent No. 7,347,998 for Targeted Gene Delivery in vivo. This patent provides additional intellectual property protection for the platform of highly advanced biotechnologies embodied in the company's leading anti-cancer agent, Rexin-G. MedSort Online Health Record System Ensures Patient Privacy and Physician Efficiency
ENCINO, Calif. -- In December 2007, MedSort.com, a premier online personal medication list management system, launched a comprehensive personal health records system - MedSort Health(TM) - which empowers consumers and patients to take control of their health records. Since January 2007, MedSort.com has been helping patients to create and manage their medication and allergy list online.
As Targeted Gene Therapy Comes of Age in Clinical Medicine, Epeius Biotechnologies Applauds Their Academic Contemporaries
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today their appreciation of the accomplishments of their contemporaries in 2007, a truly remarkable year in terms of biomedical research, scholarship, and gonzo journalism. It was a year in which a definitive meeting entitled "In Vivo Barriers to Gene Delivery" was held at the prestigious Cold Spring Harbor Laboratory, where Nobel laureate James Watson presides, or shall we say presided.
ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today that the company has received a Certificate of Product Registration for Rexin-G(R) from the Philippine Bureau of Food and Drugs (BFAD), enabling the commercialization of its lead product as a safe and effective treatment for a broad spectrum of intractable cancers.
FDA Approves the Opening of a Phase II Registration Protocol Using REXIN-G for Osteosarcoma
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today that the company has taken a major step toward the commercialization of its lead product with the opening of a Phase II Registration Protocol using Rexin-G for osteosarcoma in the United States. Following the accelerated approval of Rexin-G for the treatment of all solid tumors by the Bureau of Food and Drugs in the Philippines, Epeius opened a number of Phase I/II clinical trials.
San Diego Office Added by Always Best Care Senior Services
SAN DIEGO, Calif. -- Always Best Care Senior Services has expanded into the San Diego area. America's premier In-Home Care, Assisted Living Placement Service, and Personal Response Company, is proud to announce seniors in San Diego can now rely on Always Best Care Senior Services for outstanding care.
Epeius Biotechnologies Leads with Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference...
SAN MARINO, Calif. and BOSTON, Mass. -- Epeius Biotechnologies Corporation today announced that Dr. Frederick L. Hall, President and CEO of Epeius Biotechnologies Inc., has accepted an invitation to give the lead keynote address on "The Advent of Pathotropic Medicine for Cancer" at the Global Pharma R&D Summit 2007 to be held in Boston MA.
Sunshine Media, Inc. Announces M.D. News Magazine to the Inland Empire Marketplace
RIVERSIDE, Calif. -- Sunshine Media Inc. a leading publisher of locally focused business-to-business magazines covering high impact sectors of the economies of the United States and Canada, has named Bobby Thompson, Publisher of M.D. News, Inland Empire Region.
New Treatments for Kidney Cancer Offer Hope, but Create Difficult Choices for Cancer Patients
SAN FRANCISCO, Calif. -- California Kidney Cancer Foundation Executive Director, Dr. David Minor will present a review of treatments for metastatic kidney cancer as presented at the most recent American Society of Clinical Oncology Conference. The presentation will be from 3 to 5 PM on September 15, 2007 at California Pacific Medical Center, 2333 Buchanan Street, San Francisco. Renowned Fertility and Hormonal Health Expert Dr. Robert Greene to Lead Sacramento Reproductive Practice
SACRAMENTO, Calif. -- The Sher Institute for Reproductive Medicine - Sacramento (SIRM-Sacramento) has announced that Dr. Robert Greene will join as full-time medical director, operating out of the Sacramento headquarters as well as the Pleasanton and newly-established Redding satellite offices.
California Biotech Company Takes Aim at Pancreatic Cancer With an Advanced Phase I/II Clinical Trial
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today that an advanced Phase I/II clinical trial using intravenous Rexin-G(TM) for pancreatic cancer that is refractory to standard chemotherapy will open in the summer of 2007 in Los Angeles, California. Rexin-G is the world's first tumor-targeted injectable gene delivery system that is designed to seek out and destroy both primary tumors and metastatic cancers that have spread throughout the body.
Osmetech Licenses Roche Hot Start® Polymerase Technology
PASADENA, Calif. -- Osmetech plc (AIM; LSE: OMH) today announced that it has been granted a non-exclusive worldwide diagnostics license from Swiss-based F. Hoffman LaRoche Ltd and its US affiliate Roche Molecular Systems Inc. (collectively "Roche") to use Hot Start(R) polymerase technology in Osmetech nucleic acid diagnostic assays.
Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announced the publication of a historic landmark in medical oncology and a definitive benchmark in the emerging field of cancer gene therapy. The first clinical report of its kind, Le Morte du Tumour - was published in the June issue of the International Journal of Oncology. Epeius Biotechnologies Gains FDA Approval for Two New Clinical Trials Using Rexin-G(TM) for Breast Cancer and Sarcoma
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today the expansion of ongoing clinical trials using Rexin-G(TM) in the United States to include breast cancer and all types of sarcomas that have failed standard chemotherapy. Following on the heels of their landmark clinical trials in the United States and abroad, the US FDA granted Orphan Drug Status for Rexin-G.
Epeius Biotechnologies to Present the Advent of Tumor Targeting Technology at C21 BioVentures Conference
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announced that Dr. Frederick L. Hall, President and CEO of Epeius Biotechnologies, has accepted an invitation to speak during the 9th annual C21 BioVentures Conference. On May 23 Dr. Hall will present the scientific principles, clinical validation, and global development status of the company's innovative tumor-targeting technology. Tehachapi Hospital Foundation Seeks Funds to Save Rural Critical Access Facility
TEHACHAPI, Calif. -- The Tehachapi Hospital Foundation, an IRS 501(c)(3) organization, is actively seeking funds to build a new hospital in a region between Lancaster and Bakersfield, CA - Tehachapi. The present Tehachapi Hospital is unable to meet state-mandated earthquake safety requirements; the existing structure cannot be retrofitted. DermHair Clinic Provides New Hope and Applies New Technique for Baldness
REDONDO BEACH, Calif. -- DermHair Clinic, a division of FineTouch Dermatology, Inc., located in Redondo Beach, Calif., offers a unique hair-restoration procedure called "Body Hair Transplantation" (BHT) where body hair is transplanted to balding areas on the head. Japanese Study Confirms Safety and Efficacy of Intravenous Rexin-G
SAN MARINO, Calif. -- Epeius Biotechnologies announced today the first results of an independent study conducted in Japan that further documents the safety and efficacy of intravenous Rexin-G in a broad spectrum of patients with chemo-resistant metastatic cancer. Although the study began in October, only two months ago, the initial reports are both encouraging and noteworthy. The lead investigator of the Japanese study, Dr. Takaki Imamura, will be presenting his findings and clinical recommendations at a special medical conference to be held in Tokyo, Japan, on December 16, 2006.
Rexin-G, The World’s First Tumor-Targeted Gene Therapy Vector, Stymies Metastatic Cancer
SAN MARINO, Calif. -- Epeius Biotechnologies recently announced the publication of clinical data from studies conducted at the University of the Philippines, Asian Hospital and Medical Center, Makati Medical Center, Manila, Philippines and Lutheran Medical Center, New York, USA, revealing the safety and single agent efficacy of Rexin-G(TM) for the treatment of a broad spectrum of chemotherapy-resistant cancers.
